CN116406287A - 治疗由病毒引起的补体介导的障碍的方法 - Google Patents

治疗由病毒引起的补体介导的障碍的方法 Download PDF

Info

Publication number
CN116406287A
CN116406287A CN202180043318.6A CN202180043318A CN116406287A CN 116406287 A CN116406287 A CN 116406287A CN 202180043318 A CN202180043318 A CN 202180043318A CN 116406287 A CN116406287 A CN 116406287A
Authority
CN
China
Prior art keywords
dose
day
eculizumab
complement
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043318.6A
Other languages
English (en)
Chinese (zh)
Inventor
吉拉利·安娜
维罗尼克·弗莱米乌斯-巴基
瑞吉斯·佩弗·德拉图尔
莎伦·巴尔
德里克·邓恩
高翔
沙姆萨·D·卡扎尼
米歇尔·默丘里
乔纳森·蒙特莱昂
斯蒂芬·奥尔蒂斯
斯科特·T·罗廷豪斯
玛蒂娜·齐默尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paris Public Medical Assistance Agency
Alexion Pharmaceuticals Inc
Original Assignee
Paris Public Medical Assistance Agency
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paris Public Medical Assistance Agency, Alexion Pharmaceuticals Inc filed Critical Paris Public Medical Assistance Agency
Publication of CN116406287A publication Critical patent/CN116406287A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180043318.6A 2020-04-16 2021-04-16 治疗由病毒引起的补体介导的障碍的方法 Pending CN116406287A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063010905P 2020-04-16 2020-04-16
US63/010,905 2020-04-16
US202063014999P 2020-04-24 2020-04-24
US63/014,999 2020-04-24
US202063019050P 2020-05-01 2020-05-01
US63/019,050 2020-05-01
US202063020195P 2020-05-05 2020-05-05
US202063020286P 2020-05-05 2020-05-05
US63/020,195 2020-05-05
US63/020,286 2020-05-05
US202063033140P 2020-06-01 2020-06-01
US63/033,140 2020-06-01
US202063063538P 2020-08-10 2020-08-10
US63/063,538 2020-08-10
PCT/US2021/027636 WO2021211940A1 (en) 2020-04-16 2021-04-16 Methods for treating a complement mediated disorder caused by viruses

Publications (1)

Publication Number Publication Date
CN116406287A true CN116406287A (zh) 2023-07-07

Family

ID=75787341

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043318.6A Pending CN116406287A (zh) 2020-04-16 2021-04-16 治疗由病毒引起的补体介导的障碍的方法

Country Status (5)

Country Link
US (1) US20230416344A1 (cg-RX-API-DMAC7.html)
EP (1) EP4135837A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023522208A (cg-RX-API-DMAC7.html)
CN (1) CN116406287A (cg-RX-API-DMAC7.html)
WO (1) WO2021211940A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
CA3161271A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
AU2020438234A1 (en) 2020-03-27 2022-09-29 Inflarx Gmbh Inhibitors of C5a for the treatment of corona virus infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗c5a抗體
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下(sc)施用抗c5抗体治疗补体相关病症
JP7821160B2 (ja) * 2020-08-13 2026-02-26 アレクシオン ファーマシューティカルズ, インコーポレイテッド 造血幹細胞移植関連血栓性微小血管症(hsct-tma)を処置するための抗c5抗体の用量及び投与
WO2024121370A1 (en) * 2022-12-09 2024-06-13 Universität Zürich Complement component 7 as a diagnostic marker and therapeutic target
US12180274B2 (en) * 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
WO2025221479A1 (en) * 2024-04-16 2025-10-23 Alexion Pharmaceuticals, Inc. Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201691481A1 (ru) * 2014-03-20 2017-02-28 Инфларкс Гмбх ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
IL307197B2 (en) 2017-07-11 2026-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
US20200230408A1 (en) * 2018-12-21 2020-07-23 Electrocore, Inc. Systems and methods for treating patients with diseases associated with replicating pathogens
WO2019227102A1 (en) * 2018-05-25 2019-11-28 Achillion Pharmaceuticals, Inc. Complement alternative pathway-associated nephropathy biomarkers
EP3802603A1 (en) * 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
EP3852874A1 (en) * 2018-09-17 2021-07-28 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure

Also Published As

Publication number Publication date
EP4135837A1 (en) 2023-02-22
WO2021211940A8 (en) 2021-11-11
US20230416344A1 (en) 2023-12-28
JP2023522208A (ja) 2023-05-29
WO2021211940A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
US20230416344A1 (en) Methods for treating a complement mediated disorder caused by viruses
JP7518764B2 (ja) 発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
AU2024266818B2 (en) Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS)
JP7577542B2 (ja) 小児患者における非典型溶血性尿毒症症候群(aHUS)の治療のための抗C5抗体の用量および投与
US20180142010A1 (en) Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
EA014106B1 (ru) Агенты, связывающиеся с мишенью в легочной ткани, для лечения респираторных заболеваний
EP3802593B1 (en) Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
US20160168237A1 (en) Method for treating a complement mediated disorder caused by an infectious agent in a patient
CA3181026A1 (en) Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
CN116194478A (zh) 皮下(sc)施用抗c5抗体治疗补体相关病症
US20230357418A1 (en) Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
JP2024509702A (ja) 急性covid-19および急性後covid-19を発症するリスクを評価するためのバイオマーカー
JP2023523096A (ja) 急性呼吸促迫症候群を治療するための組成物および方法
JP2023533658A (ja) 急性呼吸窮迫症候群を治療又は予防する方法
EP4126945B1 (en) Methods and treatment involving excess free light
JP2025532869A (ja) 慢性腎疾患を有する患者における心臓手術関連急性腎損傷(csa-aki)及び/又はその後の主要な腎臓有害事象(make)を予防又は最小化するための抗c5抗体の投薬及び投与
EA043233B1 (ru) ДОЗИРОВАНИЕ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ПАРОКСИЗМАЛЬНОЙ НОЧНОЙ ГЕМОГЛОБИНУРИЕЙ (PNH) И АТИПИЧНЫМ ГЕМОЛИТИКО-УРЕМИЧЕСКИМ СИНДРОМОМ (aHUS)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination